// App-Quantinova.ai

: ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Researchers

Presenter

  • Matthew S. Davids

Principal Investigators

  • Saad S. Kenderian

  • Ian W. Flinn

  • Brian T. Hill

  • Michael Maris

  • Paolo Ghia

  • Michael Byrne

  • Nancy L. Bartlett

  • John M. Pagel

  • Yan Zheng

  • Justyna Kanska

  • Wangshu Zhang

  • Behzad Kharabi Masouleh

  • Enrique Granados

  • Javier Pinilla Ibarz

Medical Centers

  • Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN

  • Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

  • Department of Medicine, Division of Hematology and Oncology, Vanderbilt University, Nashville, TN

  • Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

  • Universita' Vita-Salute San Raffaele C.F. , Milano, Italy

  • Sara Cannon Research Institute, Denver, CO

  • Divison of Oncology, University of Washington School of Medicine, Swedish Cancer Institute, Seattle, WA

  • Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO

Locations

  • United States

  • Italy

Companies

  • Kite Pharma, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Lymphomas

Biomarkers

  • Bruton tyrosine kinase

  • Coxsackie Virus And Adenovirus Receptor

  • Lymphocyte count

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

  • Ibrutinib

Outcome

  • N/A

Study Design

  • Multinational

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved